Experimental cancer drug GEN2 trial halted early

NCT ID NCT06391918

Terminated Disease control Sponsor: GenVivo, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called GEN2, given with another drug (valganciclovir), in 37 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, 46202, United States
NEXT Oncology

Fairfax, Virginia, 22031, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
UCLA Hematology-Oncology

Los Angeles, California, 90095, United States
University of Iowa Health Care

Iowa City, Iowa, 52242, United States
University of Southern California-Keck School of Medicine

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.